Breastfeeding warning
Use during breastfeeding only on medical advice.
Leaflet FEMOSTON MINI 0.5mg / 2.5mg film-coated tablets
- Product code:
- W59812001
- Quantity:
- 14
- Indicated for:
- menopausal symptoms
- Route of administration:
- oral
- Substance:
- estradiol + dydrogesterone (estrogen + progestogen)
- ATC
- G03FA14 — Genito urinary system and sex hormones | Progestogens and estrogens in combination | Progestogens and estrogens, fixed combinations
Precautions:
Pregnancy warning
Use during pregnancy only on medical advice.
The combination of estradiol and dydrogesterone is used in hormone replacement therapy (HRT) for postmenopausal women to relieve symptoms associated with estrogen deficiency, such as hot flashes, night sweats, vaginal dryness, and to prevent osteoporosis.
- Estradiol is an estrogen hormone that replaces the natural estrogen levels that decrease during postmenopause.
- Dydrogesterone is a progestogen that protects the uterine lining (endometrium) from the negative effects of estradiol, preventing endometrial hyperplasia.
This combination is taken orally, usually once daily, as directed by a doctor.
Common side effects include nausea, headache, breast tenderness, irregular vaginal bleeding, and mood changes. Rarely, more serious reactions such as thromboembolism, breast cancer, or uterine cancer may occur, requiring careful medical monitoring.
The treatment should be used as prescribed by a doctor, and the benefits and risks should be periodically assessed.
- Estradiol is an estrogen hormone that replaces the natural estrogen levels that decrease during postmenopause.
- Dydrogesterone is a progestogen that protects the uterine lining (endometrium) from the negative effects of estradiol, preventing endometrial hyperplasia.
This combination is taken orally, usually once daily, as directed by a doctor.
Common side effects include nausea, headache, breast tenderness, irregular vaginal bleeding, and mood changes. Rarely, more serious reactions such as thromboembolism, breast cancer, or uterine cancer may occur, requiring careful medical monitoring.
The treatment should be used as prescribed by a doctor, and the benefits and risks should be periodically assessed.
General data about FEMOSTON MINI 0.5mg / 2.5mg
- Substance:
- estradiol + dydrogesterone
- Date of latest medicines list:
- 02-10-2013
- Product code:
- W59812001
- Concentration:
- 0.5mg / 2.5mg
- Pharmaceutical form:
- film-coated tablets
- Quantity:
- 14
- Product type:
- Original
- Prescription status:
- P-6L — Medicines dispensed with a medical prescription that is not retained by the pharmacy and may be renewed; the prescription may be used for 6 months from the date of issue.
Concentrations available for estradiol + dydrogesterone
- 0.5mg/2.5mg
- 1mg/10mg
- 1mg/5mg
- 2mg/10mg